Intestinal macrophages (MO) can be activated to kill intracellular Mycobacterium avium complex (MAC) but have differentiated ability to produce cytokines.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Intestinal macrophages (MO) can be activated to kill intracellular Mycobacterium avium complex (MAC) but have differentiated ability to produce cytokines.

Abstr Gen Meet Am Soc Microbiol. 1993;93:181 (abstract no. U-69). Unique Identifier : AIDSLINE ASM93/93291800
Hsu N; Young L; Bermudez LE; Kuzell Institute, San Francisco, CA.

Abstract: Current evidence suggest that the gut is the main portal of entry of MAC infection in AIDS patients. Bacterial invasion of the intestinal mucosa presumably occurs throughout the M cells where they come in contact with immuno-competent cells such as MO, T and B lymphocytes. As mucosal MO are the first line of defense, we examined their ability to control MAC infection. Mouse intestinal MO were purified and infected MAC (101, serovar 1 and 862486, serovar 16). MO were stimulated with recombinant TNF, IFN gamma, GM-CSF, and M-CSF at various concentrations for 4 days, and the number of viable intracellular organisms quantitated. MO inhibited the growth of MAC 862486 but not of MAC 101. TNF, IFN gamma, and GM-CSF but not M-CSF were associated with significant killing of intracellular MAC (58 to 76%). In comparison with peritoneal MO, intestinal MO were more efficient as antigen presenting cell, as evidenced by the ability of lymphocytes to produce IL-2 in mixed culture. In contrast, the production of TNF (but not the production of IL-6) by intestinal MO stimulated with LPS or MAC was decreased when compared with the release of TNF by peritoneal and splenic MO submitted to the same stimuli. In summary, intestinal MO can be activated to cytokines but have differentiated ability to produce cytokines which can influence the course of MAC infection.

Keywords: Animal Antigen-Presenting Cells/IMMUNOLOGY Cell Survival/DRUG EFFECTS Cytokines/*BIOSYNTHESIS Granulocyte-Macrophage Colony-Stimulating Factor/PHARMACOLOGY Human Interferon-gamma, Recombinant/PHARMACOLOGY Interleukin-2/BIOSYNTHESIS Interleukin-6/BIOSYNTHESIS Intestines/MICROBIOLOGY Lymphocytes/IMMUNOLOGY *Macrophage Activation Macrophage Colony-Stimulating Factor/PHARMACOLOGY Macrophages/DRUG EFFECTS/*IMMUNOLOGY Mice Mycobacterium avium Complex/*IMMUNOLOGY Recombinant Proteins/PHARMACOLOGY Tumor Necrosis Factor/PHARMACOLOGY ABSTRACT
930930
M9391171

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .